Merck Sharp + Dohme Corp.

Merck Sharp & Dohme LLC

Mihir Mandal

Jing Su

Fa-Xiang Ding

Haifeng Tang

John P Caldwell

Christina B Madsen-Duggan

Marc A Labroli

Ginny Dai Ho

Lihu Yang

David Brian Olsen

Takao Suzuki

William K Hagmann

Qun Dang

Sheo B Singh

Robert R Wilkening

Guoqing Li

Dongfang Meng

Li Xiao

Shuzhi Dong

William J Greenlee

Tesfaye Biftu

Zhaoning Zhu

Alexander Pasternak

Barbara A Pio

Jinlong Jiang

Zhicai Wu

David L Sloman

Haiqun Tang

Helen Y Chen

Xin Gu

Harry R Chobanian

Yan Guo

Clare London

Timothy A Blizzard

Shu-Wei Yang

Weidong Pan

Sookhee Nicole Ha

Katherine Young

Christine Yang

Zheng Tan

Sandra J Koseoglu

Sang Ho Lee

Terry Roemer

Christopher Michael Tan

Hao Wang

Jianping Pan

Dexi Yang

James M Apgar

Dann Parker

Reynalda DeJesus

Reynalda De Jesus

Charles J Gill

Ronald E Painter

Zhiqiang Zhao

Jacqueline D Hicks

Timothy Allen Blizzard

Yuhua Huang

Hong Dong Chu

Dipshikha Biswas

Matthew Lombardo

David N Hunter

Xiaoshen Ma

Lanying You

Andrew J Hoover

Johnny Zhaoning Zhu

Alex Pasternak

Reynalda Dejesus

Yongxin Han

Zahid Hussain

Thomas H Graham

Novel compounds of the structural formula I, and the pharmaceutically acceptable salts thereof, are inhibitors of TarO and may be useful in the prevention, treatment and suppression of diseases mediated by TarO, such as bacterial infections, including gram negative bacterial infections and gram positive bacterial infections such as MRSA and MRSE, alone or in combination with a &#x3b2;-lactam antibiotic.

Benzimidazoles and indoles as taro inhibitors

Oxazolidinones as TarO inhibitors

Novel compounds of the structural formula I, and the pharmaceutically acceptable salts thereof, are inhibitors of TarO and may be useful in the prevention, treatment and suppression of diseases mediated by TarO, such as bacterial infections, including gram negative bacterial infections and gram positive bacterial infections such as MRSA and MRSE, alone or in combination with a &#x3b2;-lactam antibiotic. 

Oxazolidinones as taro inhibitors

The present invention relates to oxazolidinone compounds of Formula (I): and pharmaceutically acceptable salts thereof, wherein A, E, and Rare as defined herein. The present invention also relates to compositions which comprise at least one oxazolidinone compound of the invention. The invention also provides methods for inhibiting growth of mycobacterial cells as well as a method of treating mycobacterial infections bycomprising administering a therapeutically effective amount of an oxazolidinone of the invention and/or a pharmaceutically acceptable salt thereof, or a composition comprising such compound and/or salt.

Oxazolidinone compounds and methods of use thereof as antibacterial agents

The present invention relates to novel nargenicin related compounds which can inhibit DnaE and have antibacterial, particularly antimycobacterial activity against. The present invention also relates to method for inhibiting growth of mycobacterial cells as well as a method of treating mycobacterial infections byby administering an antimycobacterially effective amount of nargenicin or a nargenicin-related compound and/or their pharmaceutically acceptable salts.

Nargenicin compounds and uses thereof as antibacterial agents

The present invention relates to compounds of formula I that are metallo-&#x3b2;-lactamase inhibitors, the synthesis of such compounds, and the use of such compounds for use with &#x3b2;-lactam antibiotics for overcoming resistance. 

Beta-tetrazolyl-propionic acids as metallo-beta-lactamase inhibitors

The present invention relates to compounds of formula (I) that are metallo-&#x3b2;-lactamase inhibitors, the synthesis of such compounds, and the use of such compounds for use with &#x3b2;-lactam antibiotics for overcoming resistance. 

Metallo-beta-lactamase inhibitors

Disclosed herein are compounds of Formula (I) or a pharmaceutically acceptable salt thereof, wherein each of the substituents is given the definition as set forth in the specification and claims. Also disclosed are pharmaceutical compositions containing the compound of Formula (I) and use of the compound in the treatment of neurodegenerative diseases or conditions such as Alzheimer's disease. 

Gamma secretase modulators

The present invention relates to bicyclic himbacine derivatives of the formula or a pharmaceutically acceptable salt thereof, wherein: X is &#x2014;O&#x2014;, &#x2014;N(R), &#x2014;C(R)(R) or &#x2014;C(O)&#x2014;; and Y is &#x2014;O&#x2014;, &#x2014;N(R), &#x2014;C(R)(R) or &#x2014;C(O)&#x2014; and the remaining variables are described herein. The compounds of the invention are effective inhibitors of the PAR-1 receptor. The inventive compounds may be used for the treatment or prophylaxis of disease states such as ACS, secondary prevention of myocardial infarction or stroke, or PAD. 

Preparation and use of bicyclic himbacine derivatives as PAR-1 receptor antagonists

Growing community of inventors

Westfield, NJ, United States of America

Mihir Mandal